Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
IMNN
Imunon, Inc.
DNA plasmid-based therapeutics align with Oligonucleotide Therapeutics.
|
$4.43M |
$4.54
+1.22%
|
|
CRVW
CareView Communications, Inc.
CareView's core offering is patient monitoring via video-based systems, including SitterView and TeleMedView components.
|
$4.39M |
$0.03
|
|
BCLI
Brainstorm Cell Therapeutics Inc.
NurOwn is a proprietary autologous cell therapy platform developed by Brainstorm for ALS and related neurodegenerative indications, directly produced and administered by the company.
|
$4.24M |
$0.65
|
|
EVTV
Envirotech Vehicles, Inc.
Medical Device Consumables: Medical supplies segment with related-party sales and cost-plus pricing indicating consumable offerings.
|
$4.22M |
$1.66
+0.91%
|
|
TTNP
Titan Pharmaceuticals, Inc.
Titan's core ProNeura technology is a long-acting drug delivery platform used for subdermal implants.
|
$4.21M |
$4.61
|
|
IDXG
Interpace Biosciences, Inc.
Interpace focuses on oncology-focused molecular diagnostics and cancer risk biomarker testing, including thyroid-related cancer risk assessment.
|
$4.12M |
$1.02
|
|
ADMT
ADM Tronics Unlimited, Inc.
Company designs and manufactures medical devices and biometric sensing technologies including diagnostics and therapeutics.
|
$4.10M |
$0.09
|
|
CLDI
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics directly develops cancer therapies (oncolytic virus platforms) targeting oncology indications.
|
$4.08M |
$1.54
|
|
ALBT
Avalon GloboCare Corp.
KetoAir breathalyzer is a directly produced diagnostic equipment device sold as a precision diagnostic product.
|
$4.02M |
$2.10
-1.64%
|
|
DFCO
Dalrada Financial Corporation
Infusion pharmacy and compounding facility fall under healthcare services & facilities.
|
$3.60M |
$0.03
|
|
BIVI
BioVie Inc.
Bezisterim is described as an orally administered small molecule therapeutic targeting inflammation-driven insulin resistance in neurodegenerative diseases, aligning with 'Oral Small Molecule Therapeutics'.
|
$3.25M |
$1.77
+0.28%
|
|
CMND
Clearmind Medicine Inc.
CMND-100 is an oral small-molecule therapeutic candidate, categorizing the company under Oral Small Molecule Therapeutics.
|
$3.17M |
$0.76
-16.75%
|
|
VERO
Venus Concept Inc.
Venus Concept produces medical aesthetic devices and robotic systems (Venus platforms, ARTAS iX) and related medical devices.
|
$3.05M |
$2.17
+1.40%
|
|
BICX
BioCorRx Inc.
BioCorRx is actively commercializing Lucemyra, an FDA-approved oral small molecule therapeutic for opioid withdrawal, expanding direct product sales.
|
$2.92M |
$0.44
|
|
AMIX
Autonomix Medical, Inc. Common Stock
Core platform is a catheter-based Neuromodulation Device designed to sense and ablate peripheral nerves.
|
$2.86M |
$1.02
-0.97%
|
|
QNRX
Quoin Pharmaceuticals, Ltd.
Lead program targets a rare disease (Netherton Syndrome) and is developed by a biotech focused on rare diseases.
|
$2.85M |
$10.69
-5.40%
|
|
GTCH
GBT Technologies Inc.
GTCH's qTerm device and biometrics relate to medical devices/biometrics category.
|
$2.77M |
$0.00
|
|
ADIL
Adial Pharmaceuticals, Inc.
Lead AUD program is a neuropsychiatric CNS therapeutic, aligning with Neuropsychiatric Drug Development.
|
$2.76M |
$0.34
-3.52%
|
|
BIOE
Bio Essence Corporation
Provides outsourced contract manufacturing (OEM) services for health-related products.
|
$2.70M |
$0.07
|
|
SILO
Silo Pharma, Inc.
Drug Delivery Platforms directly describes Silo's intranasal and implantable drug delivery technologies (SPC-15, SPC-14, SP-26).
|
$2.43M |
$0.55
+0.70%
|
|
CARM
Carisma Therapeutics, Inc.
CAR-Macrophage platform is a cell-therapy technology, directly representing Carisma's core product category.
|
$2.36M |
$0.15
+160.68%
|
|
ELAB
PMGC Holdings Inc.
Contract Research Organizations (CRO)-like R&D capabilities through PMGC Research Inc. for biotech development.
|
$2.33M |
$5.87
-2.74%
|
|
YBGJ
Yubo International Biotech Limited
Endometrial stem cell research and potential cell therapies (core biotech focus).
|
$2.32M |
$0.01
|
|
BIAF
bioAffinity Technologies, Inc.
CyPath Lung testing is delivered as a laboratory testing service via Precision Pathology Laboratory Services (PPLS).
|
$2.23M |
$2.46
+0.61%
|
|
CANF
Can-Fite BioPharma Ltd.
Company focuses on orally bioavailable small molecule therapeutics targeting A3AR, including Piclidenoson and Namodenoson.
|
$2.12M |
$0.42
|
|
AAGH
America Great Health
Focus on peptide/protein therapeutics as a core research and therapeutic development area.
|
$2.12M |
$0.00
|
|
JAGX
Jaguar Health, Inc.
Jaguar Health focuses on crofelemer-based therapies delivered orally, aligning with the Oral Small Molecule Therapeutics category.
|
$1.98M |
$1.95
+0.52%
|
|
ZCMD
Zhongchao Inc.
ZCMD provides healthcare information services and patient management systems to healthcare professionals and institutions, fitting Healthcare Services & Facilities.
|
$1.81M |
$0.70
+2.50%
|
|
VYST
Vystar Corporation
RxAir medical-grade air purification devices and FDA-cleared units position the company in medical devices and biometrics.
|
$1.63M |
$0.09
|
|
AIM
AIM ImmunoTech Inc.
Ampligen is AIM ImmunoTech's flagship oncology/immunotherapy platform and is being developed with cancer indications (pancreatic and ovarian cancer) in combination with checkpoint inhibitors.
|
$1.60M |
$2.10
|
|
GRTX
Galera Therapeutics, Inc.
Company directly develops oncology therapeutics, including its NOS pan-inhibitor and SOD mimetics for cancer indications.
|
$1.47M |
$0.03
|
|
VTAK
Catheter Precision, Inc.
VTAK's VIVO System is a cardiology-focused medical device for non-invasive 3D mapping, aligning with Cardiology Devices.
|
$1.42M |
$2.45
+2.08%
|
|
AEMD
Aethlon Medical, Inc.
Hemopurifier is a blood purification device, the core product offering of Aethlon Medical.
|
$1.36M |
$5.51
+4.75%
|
|
NAOV
NanoVibronix, Inc.
Core business is medical devices, including legacy wound/pain therapies and new ENvue enteral-feeding technology.
|
$1.33M |
$5.09
-0.97%
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Diagnostics is developing pretreatment diagnostic tests for prostate cancer (PC-RAD) and theranostics, aligning with companion diagnostics.
|
$1.30M |
$3.00
-1.64%
|
Showing page 37 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
